 TEL AVIV, Israel and RALEIGH, NC, May 26, 2021 PRNewswire -- RedHill Biopharma Ltd. Nasdaq: RDHL RedHill or the Company, a specialty biopharmaceutical company, today announced receipt of two Notices of Allowance from the U.S. Patent and Trademark Office USPTO covering opaganib1 and RHB-107 upamostat2 as methods for the treatment of COVID-19 caused by the SARS-CoV-2 virus. 